The dermorphin-derived peptide [Dmt 1 ]DALDA (H-Dmt-D-ArgPhe-Lys-NH 2 ; Dmt, 2Ј,6Ј-dimethyltyrosine) labels -opioid receptors with high affinity and selectivity in receptor binding assays. In previous studies, [Dmt 1
1
]DALDA displayed a mechanism of action distinct from that of morphine, as evidenced by its insensitivity to antisense probes reducing morphine analgesia and incomplete cross tolerance to morphine. In an effort to further elucidate the unusual mechanism of action, [ DALDA is a very potent -selective analgesic, its binding characteristics and its ability to stimulate GTP␥S binding differed from that of the classical -opioid peptide DAMGO.
-Opioids continue to be widely used for the treatment of moderate to severe pain. -Opioids and opioid peptides comprise a large, diverse group of ligands, typically classified by their ability to bind with high affinity and selectivity to the -opioid receptor and to elicit such pharmacological actions as analgesia, inhibition of gastrointestinal transit, respiratory depression, and the induction of tolerance and dependence. There are several lines of evidence from both clinical and animal studies to suggest that -opioid analgesics vary considerably in their actions (Wolozin and Pasternak, 1981; Payne and Pasternak, 1992; Rossi et al., 1995; Pasternak, 2001 ). -Opioids, such as heroin, morphine-6␤-glucuronide (M6G), 6-acetylmorphine, and fentanyl retain their analgesic potencies in CXBK mice, a strain that is insensitive to morphine (Rossi et al., 1996) , and they display limited crosstolerance to morphine in animal studies (Lange et al., 1980; Rossi et al., 1996) and clinically (Cherny et al., 2001 ). The antagonist 3-methylnaltrexone selectively blocks the actions of heroin, 6-acetylmorphine, and M6G more potently than morphine (Brown et al., 1997a; Walker et al., 1999) . Antisense mapping studies on the cloned -opioid receptor clone 1 (MOR-1) find different sensitivity profiles for morphine compared with heroin and M6G (Rossi et al., 1995 (Rossi et al., , 1996 . In addition, M6G, heroin and 6-acetylmorphine retained their analgesic activity in a knockout mouse with disruption of exon 1 of the MOR-1 receptor that was totally insensitive to morphine (Schuller et al., 1999) . Although exon 1 has been deleted, there is still expression of MOR-1 splice variants in this knockout mouse, as demonstrated by both reverse transcriptase-polymerase chain reaction and immunohistochemistry (Schuller et al., 1999; Pan et al., 2001; C. Abbadie, J. Pintar, and G. W. Pasternak, unpublished observations) .
The dermorphin analog [Dmt 1 ]DALDA (H-Dmt-D-Arg-PheLys-NH 2 ; Dmt, 2Ј,6Ј-dimethyltyrosine) (Schiller et al., 2000) displays a very unique pharmacology that differs from that of morphine, as evidenced by its insensitivity to antisense probes that reduce morphine (exons 1, 4, 5, 6, 7, 8, 9 , and 10) or M6G (exon 2) analgesia, its incomplete cross-tolerance to morphine (Neilan et al., 2001; Riba et al., 2002) , and persistent analgesia in a MOR-1 knockout mouse (Neilan et al., 2003) . This peptide also is an effective analgesic in morphine-insensitive CXBK mice (Neilan et al., 2001) . [Dmt 1 ]DALDA has a long duration of action and is metabolically stable with limited penetration of the placental barrier . Radioligand binding studies have proved to be a valuable tool in investigating the mechanisms of action of -opioids. Detailed binding experiments reported over twenty years ago first proposed multiple classes of -binding sites (Wolozin and Pasternak, 1981) . More recent studies using [ 3 H]M6G also support the concept of -receptor heterogeneity (Brown et al., 1997b) . In an attempt to further investigate the more unusual aspects of its pharmacology, we now have characterized the receptor binding profile of [ 
Materials and Methods
Drugs. For the preparation of tritiated [Dmt 1 ]DALDA, a precursor peptide containing 2Ј,6Ј-dimethyl-3Ј,5Ј-diiodotyrosine [Tyr(2Ј,6Ј-Me 2 -3Ј,5Ј-I 2 ] needed to be synthesized. Fmoc-Dmt-OH was iodinated by treatment with I 2 in the usual manner to yield Fmoc-Tyr(2Ј,6Ј-Me 2 -3Ј,5Ј-I 2 )-OH. This protected amino acid was then used in the solid-phase synthesis of H-Tyr(2Ј,6Ј-Me 2 -3Ј,5Ј-I 2 )-D-Arg-Phe-Lys-NH 2 according to a protocol published elsewhere (Schiller et al., 2000) . The peptide was purified by preparative reversed-phase chromatography, and its structure was confirmed by fast atom bombardment mass spectrometry. Receptor Binding.Membranes were prepared as reported previously (Clark et al., 1988 (Clark et al., , 1989 . Tissue or cells were homogenized in 50 volumes of 50 mM Tris buffer, pH 7.7, containing 10 M phenylmethylsulfonyl fluoride, 100 mM NaCl, and 1 mM K ϩ EDTA. The homogenate was incubated for 15 min at 25°C, centrifuged at 39,000g for 45 min, resuspended in 0.32 M sucrose, and frozen at Ϫ80°C. Binding was performed in potassium phosphate buffer (50 mM; pH 7.4), containing MgSO 4 (either 1 or 5 mM, respectively) for assays with
Reactions were incubated at 25°C for 60 min, with the exception of dissociation and association binding which used the indicated time points. Assay volumes were 3 ml for calf thalamic and frontal cortex membranes, 2 ml for guinea pig cerebellum membranes and calf striatal membranes, and 1 ml for spinal cord, whole mouse brain, and CHO cell membranes. Protein concentration was 3 mg/ml wet weight of tissue for all calf brain and guinea pig cerebellar membranes and 150 g for binding assays using CHO cell membranes. Reactions were terminated by rapid filtration over glass fiber filters that then were subjected to liquid scintillation counting. For assays using
DALDA, filters were soaked in 0.5% (w/v) polyethylimine solution for 5 min before using. Nonspecific binding, which typically represented 15% of total binding, was determined using levallorphan (1 M) Sensitivity toward Ions and Nucleotides. -Opioid receptor binding is modulated by a variety of ions and nucleotides, with the binding of agonists and antagonists generally affected in opposite ways (Pert et al., 1973; Pasternak et al., 1975; Childers and Snyder, 1980) . In general divalent cations enhance -opioid agonist binding, leaving antagonist binding unaffected. Conversely, sodium ions and guanine nucleotides markedly reduce agonist, but not antagonist, binding. (Pasternak et al., 1975 (Bare et al., 1994; Zimprich et al., 1995; Pan et al., 1999 Pan et al., , 2000 Pan et al., , 2001 (Cheng and Prusoff, 1973) . Results are mean Ϯ S.E.M. of at least three independent K i determinations. Twoway analysis of variance reveals significant differences (P Ͻ 0.001). The differences among the competitors for each radioligand were significant, but no significant differences were seen for a specific competitor between the radioligands. ]DALDA still was almost 30-fold more effective in stimulating GTP␥S binding in MOR-1 than DAMGO after taking into consideration the differences in binding affinities. We also observed a similar enhanced relative potency for the other clones, but they were more modest, ranging from only 3.5-fold for MOR-1E to 10.4-fold for MOR-1D (Table 2) . In all cases, [Dmt 1 ]DALDA activated GTP␥S binding far more potently than DAMGO. Together, these observations illustrate differences between the two drugs in their activation of these receptors.
Discussion
Overall, [ 3 H][Dmt 1 ]DALDA shows high affinity and selectivity for the -opioid receptor, as well as a regional distribution typical for -opioid binding, with highest levels of binding in the striatum and thalamus. Yet, [Dmt 1 ]DALDA displays unique characteristics in both receptor and GTP␥S binding assays that distinguish it from DAMGO.
-Opioid receptor binding has been extensively characterized over the past 30 years. A variety of ions and treatments have documented the ability to distinguish between agonist and antagonist binding, findings that were then generalized to other G protein-coupled receptors. For example, the ability of sodium ions to selectively enhance antagonist and inhibit agonist binding was first described with -opioid receptors (Pert et al., 1973) , as were the ability of a number of divalent cations to selectively enhance agonist binding (Pasternak et al., 1975) . Guanine nucleotides also distinguish between agonist and antagonist binding, lowering the binding of agonists but not antagonists (Childers and Snyder, 1980 (Neilan et al., 2001; Shimoyama et al., 2001; Riba et al., 2002) . Thus, it was not surprising that it remained more potent in the GTP␥S binding studies. However, the presence of ceiling effects compared with DAMGO in both mouse brain and calf striatum imply that it is a partial agonist in these tissues with an efficacy below that of DAMGO, whereas it retained full agonist activity in the spinal cord. Although its maximal stimulation varied among the tissues, its EC 50 value remained the same.
The increased spinal cord efficacy observed for [Dmt 1 ]DALDA is consistent with its extraordinary intrathecal analgesic potency in vivo. However, other factors may also be important. Synergistic interactions between -opioid and ␣ 2 -agonists at the level of the spinal cord have been widely reported (Ossipov et al., 1989 (Ossipov et al., , 1990 Fairbanks et al., 2002) , and in a recent study the ␣ 2 -adrenergic antagonist yohimbine significantly attenuated [Dmt 1 ]DALDA-mediated intrathecal analgesia in rats (Shimoyama et al., 2001) . Therefore, it is interesting to speculate whether the increased efficacy of [Dmt 1 ]DALDA in spinal cord membranes is due in part to an interaction with other receptors, such as the ␣ 2 -receptor. However, in preliminary studies yohimbine at concentrations as high as 100 nM failed to compete The Oprm gene, which encodes MOR-1 and its variants, is large (Ͼ250 kb) and has a complex pattern of alternative splicing (Bare et al., 1994; Zimprich et al., 1995; Pan et al., 1999 Pan et al., , 2000 Pan et al., , 2001 . In vivo and in vitro studies using brain and/or spinal cord membranes, the overall actions of [Dmt 1 ]DALDA presumably reflect the summation of its in- ]GTP␥S was determined in calf striatal membranes (A), whole mouse brain membranes (B), and spinal cord membranes (C). All stimulations were normalized to the values seen with maximal stimulation with DAMGO (10 M), which was assigned the value of 100%. EC 50 values and normalized maximal stimulations calculated using GraphPad Prism. Each value represents the mean Ϯ S.E.M for at least three independent determinations. Some S.E.M. were smaller than the symbol and were not shown.
teractions with a variety of splice variants of the -receptor. Therefore, we also examined the effects of [Dmt 1 ]DALDA on a series of variants individually expressed in CHO cells. These variants differ from MOR-1 itself and each other only at the tip of the intracellular COOH tail of the receptor. All these variants selectively bind -opioids with high affinity, but show subtle differences in affinity for certain compounds across the variants, particularly the endogenous ligands ␤-endorphin and dynorphin A (Pan et al., , 2000 (Pan et al., , 2001 . These variants also differ functionally among themselves. Internalization has been well described for MOR-1 (Burford et al., 1998; Keith et al., 1998) . In these studies, DAMGO, but not morphine, internalizes MOR-1. When expressed in HEK293 cells, however, MOR-1D and MOR-1E internalize in response to either DAMGO or morphine treatment, whereas MOR-1 and MOR-1C only internalize in response to DAMGO treatment and not with morphine (Koch et al., 2001) . In vivo, MOR-1 internalizes in response to DAMGO, but not morphine, whereas MOR-1C internalizes with both (Abbadie and Pasternak, 2001) . The ability of morphine to internalize MOR-1C in neurons in the brain and not HEK293 cells may be due to a variety of issues, such as the overexpression of the protein in the HEK293 cells, the different environment of the receptor, and the repertoire of associated proteins.
In ]DALDA seemed to have full agonist activity, giving maximal responses equivalent to those of DAMGO. The difference in structure among the variants is limited to the terminal amino acids of the intracellular COOH tail, far away from the binding pocket formed by the transmembrane domains. Although prior work from our laboratory has shown subtle differences in affinity of several endogenous opioid peptides among the variants, most -drugs show little difference (Pan et al., , 2000 (Pan et al., , 2001 (Pan et al., , 2000 , with the exception of MOR- 
